A Phase 2 interventional study of AGN-151607-DP and Placebo for AGN-151607-DP in Ventral Hernia, sponsored by AbbVie. Recruiting at 13 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Hernia, Ventral with a site in United States — 14 open to participants now, 24 under way, none of them phase 3. Hernia, Ventral · United States.
Among the 94 studies in Hernia, Ventral with a site in United States, this one is the 13th largest by planned enrollment of the 70 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 21 of the 23 other live ones, and was the 88th registered.
230 studies on the registry are indexed under Hernia, Ventral; 45 are open to participants now.
Browse Hernia, Ventral studies →14 of the 94 studies in Hernia, Ventral with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+
Lucas Beffa · Sites in United States
Ages 18+ · Healthy volunteers
Stanford University · Sites in United States
Ages 19+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Hernia, Ventral studies recruiting now, 19 (73%) set no upper age limit and 4 (15%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 90 across 153 interventional studies indexed under Hernia, Ventral.
Median enrollment 100 across the 70 interventional studies, 63 across the 24 observational. Of the 59 that completed or were terminated, 31 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 94 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 2 studies filed under Hernia, Ventral — fewer than ten, so there is no comparison to draw.
10 of the studies in Hernia, Ventral with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04718168W.L.Gore & AssociatesGORE® ENFORM Biomaterial Product Study | 2026-12 |
| NCT07639281Tori DotsonOpioid Education Ventral Hernia Repair | 2026-12 |
| NCT07874724University of South FloridaCryoneurolysis for Abdominal Wall Relaxation Prior to Ventral Hernia Repair | 2027-03-01 |
| NCT04779918Tela Bio IncVentral or Inguinal Hernia, Robotically Repaired With OviTex Mesh | 2027-03-30 |
| NCT06874413Prisma Health-UpstateTargeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Ventral Hernia Repair | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 94 studies in Hernia, Ventral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closing the belly wall after open ventral hernia surgery, without needing a complex procedure. Adverse Events and change in disease activity will be assessed.
AGN-151607-DP is an investigational drug being developed to treat ventral hernia. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 200 adult participants with midline ventral hernia needing open surgical repair will be enrolled in approximately 30 sites in the United States.
Participants will receive intramuscular injections of AGN-161607-DP or matching placebo on Day 1. Duration of the study is approximately 25 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Midline ventral hernia requiring open surgical repair.
Exclusion Criteria:
Participants will receive AGN-151607-DP Dose A on Day 1.
Drug: AGN-151607-DP
Participants will receive AGN-151607-DP Dose B on Day 1.
Drug: AGN-151607-DP
Participants will receive AGN-151607-DP Dose C on Day 1.
Drug: AGN-151607-DP
Participants will receive Placebo for AGN-151607-DP on Day 1.
Drug: Placebo for AGN-151607-DP
Intramuscular Injection
Intramuscular Injection
Percentage of Participants Achieving Primary Fascial Closure (PFC) Without Use of Component Separation Technique (CST) in Open Ventral Hernia Surgical Repair
PFC will be defined as the ability to achieve fascia to fascia midline approximation.
Time frame: Up to approximately 1 Month
Percentage of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 25 Months
Percentage of Participants Achieving PFC
PFC will be defined as the ability to achieve fascia to fascia midline approximation.
Time frame: Up to approximately 1 Month
Percentage of Participants With Usage of CST for the Purpose of PFC
Percentage of participants with usage of CST will be assessed.
Time frame: Up to approximately 1 Month
Number of Lateral Abdominal Wall Muscles Released to Achieve PFC
Number of lateral abdominal wall muscles released to achieve PFC will be assessed.
Time frame: Up to approximately 1 Month
Change From Baseline in Length of Lateral Abdominal Wall Complex as Measured by Abdominal CT Scan in Supine Position Prior to Surgical Repair
Change in length of lateral abdominal wall complex will be assessed.
Time frame: Up to approximately 1 Month
Change From Baseline in Length of Lateral Abdominal Wall Complex as Measured by Abdominal CT Scan Performing Valsalva Maneuver Prior to Surgical Repair
Change in length of lateral abdominal wall complex will be assessed.
Time frame: Up to approximately 1 Month
Change From Baseline in Width to the Hernia Defect as Measured by Abdominal CT Scan in Supine Position Prior to Surgical Repair
Change in width to the hernia defect will be assessed.
Time frame: Up to approximately 1 Month
Change From Baseline in Width to the Hernia Defect as Measured by Abdominal CT Scan Performing Valsalva Maneuver Prior to Surgical Repair
Change in width to the hernia defect will be assessed.
Time frame: Up to approximately 1 Month
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Sep 2028, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A